## Antidiabetic Drug Classes and Mechanisms ### Metformin **Key Point:** Metformin is a biguanide that reduces hepatic glucose production and improves peripheral insulin sensitivity without stimulating insulin secretion. - Does not cause hypoglycemia as monotherapy (glucose-independent) - First-line agent for Type 2 diabetes - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to lactic acidosis risk ### Sulfonylureas (e.g., Glipizide, Gliclazide) **Key Point:** Sulfonylureas directly stimulate pancreatic beta cells via ATP-sensitive potassium channel closure, causing insulin release. - High hypoglycemia risk, especially with renal impairment or fasting - Weight gain (due to increased insulin levels) - Second-line agents in modern practice ### SGLT2 Inhibitors (e.g., Empagliflozin, Dapagliflozin) **Key Point:** SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal tubule, increasing urinary glucose excretion. - **Renal safety:** Can be used in mild-to-moderate CKD (eGFR 20–90 mL/min/1.73m²). Contraindicated only when eGFR <20 mL/min/1.73m² (not <30) - Cardiovascular and renal protective effects (reduce HF hospitalizations, slow CKD progression) - No hypoglycemia risk - May cause genital mycotic infections and euglycemic DKA (rare) ### GLP-1 Receptor Agonists (e.g., Exenatide, Liraglutide, Semaglutide) **Key Point:** GLP-1 agonists enhance glucose-dependent insulin secretion and slow gastric emptying. - Weight loss and cardiovascular benefits (reduced MI, stroke, CV death) - No hypoglycemia risk when used alone - Nausea common initially - Contraindicated in personal/family history of medullary thyroid carcinoma ### Why Option 3 is Incorrect **High-Yield:** SGLT2 inhibitors are **not contraindicated in all CKD patients**. The cutoff is eGFR <20 mL/min/1.73m², not <30. Many patients with eGFR 20–90 benefit from SGLT2 inhibitors for renal and cardiac protection. The statement incorrectly generalizes that SGLT2 inhibitors are "unsuitable for any patient with chronic kidney disease," which is false and contradicts current guidelines (KDIGO 2022, ADA Standards of Care). ### Comparison Table | Agent Class | Mechanism | Hypoglycemia Risk | Weight | CKD Safety | CV/Renal Benefit | | --- | --- | --- | --- | --- | --- | | **Metformin** | ↓ HGP, ↑ insulin sensitivity | No | Neutral | eGFR <30: CI | Neutral | | **Sulfonylurea** | ↑ Beta-cell insulin release | High | ↑ | eGFR <30: caution | No | | **SGLT2i** | ↑ Urinary glucose | No | ↓ | eGFR <20: CI; 20–90: safe | Yes (HF, CKD) | | **GLP-1 RA** | ↑ Glucose-dependent insulin, ↓ gastric emptying | No (alone) | ↓ | Safe | Yes (CV, weight) | **Clinical Pearl:** In a patient with Type 2 diabetes and CKD Stage 3b (eGFR 30–44), SGLT2 inhibitors are now preferred agents for renal and cardiovascular protection, not contraindicated. Current guidelines actively recommend them. [cite:ADA Standards of Care 2023, KDIGO 2022 CKD-DM Guideline]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.